The Latest

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Pfizer’s obesity-focused pact with YaoPharma is its second large licensing deal with a China-based drugmaker this year, following an earlier, multibillion-dollar alliance with 3SBio.

    Updated 22 hours ago
  • A hand holds a smartphone displaying an app with a calming design, featuring an illustration of a relaxed person and weather forecasts. Background is softly blurred.
    Image attribution tooltip

    Aptar Digital Health

    Image attribution tooltip
    Sponsored by Aptar Digital Health

    How digital companion apps unlock value across the drug lifecycle

    Where companion apps unlock value across the full drug lifecycle, from Pre-Rx to Post-Rx.

  • A 3D illustration of a human liver.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay

    The deal, which includes another $200 million in potential payouts, hands the California biotech a candidate in late-stage testing for the most severe form of viral hepatitis. 

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar

    Dyne is readying a competitor to Sarepta’s Exondys 51. Elsewhere, a pair of obesity drugs showed promise and Kymera’s protein-degrading medicine displayed “biologic-like or better efficacy,” according to one analyst.

  • Physicians, researchers and healthcare professionals attend ASCO's annual Meeting on June 2, 2023 in Chicago.
    Image attribution tooltip

    ASCO / Nick Agro

    Image attribution tooltip

    The top biopharma conferences in 2026

    Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch next year.

  • The Vertex Pharmaceuticals building in daylight on the Boston Seaport.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex CRISPR therapy hits early goal in children with blood disorders

    Casgevy, now a "national priority" drug, helped kids with sickle cell and beta thalassemia, results which may help toward a label expansion and stronger commercial uptake.

  • A photo of several members sitting side by side with a blue CDC background and screen that says U.S. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices
    Image attribution tooltip
    Elijah Nouvelage via Getty Images
    Image attribution tooltip
    Vaccines

    RFK Jr.’s hand-picked panel questions childhood vaccine schedule

    After weakening an endorsement for the hepatitis B vaccine, ACIP began debating the merits of the protocol used to inoculate U.S. children against many infectious diseases.

  • blood cells lab
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Hemophilia gene therapies are struggling on the market, even as innovation soars

    The business case for hemophilia gene therapy still isn’t adding up due to persistent market barriers.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech’s M&A outlook is uncertain. Track the deals that are happening here.

    Mirum Pharmaceuticals is paying $250 million in cash and $370 million in stock for startup Bluejay Therapeutics, which is developing a treatment for chronic hepatitis D infections. 

    Updated Dec. 8, 2025
  • People in business attire site around tables in a conference room.
    Image attribution tooltip
    Elijah Nouvelage / Stringer via Getty Images
    Image attribution tooltip
    Vaccines

    ‘Discredited’ CDC panel weakens endorsement for newborns’ hepatitis B shot

    After initially delaying a vote, ACIP backed a softer stance that dissenting members warned would cause harm to children in the future.

    Updated Dec. 5, 2025
  • Boxes of COVID-19 vaccines from Pfizer and Moderna sit side by side.
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip
    Vaccines

    12 former FDA chiefs blast Prasad’s move to toughen vaccine standards

    In an article published in NEJM, nearly all living ex-FDA commissioners lambasted the CBER head’s plans to use a probe into COVID vaccine safety to upend longstanding regulatory protocols.

    FDA
  • A person in a dark business suit sits at a desk with a microphone.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    Tracey Beth Høeg, top Makary deputy, named head of FDA drug office

    Høeg, a COVID-19 vaccine critic who’s been serving as a special assistant to the commissioner, will be the fifth person this year to run CDER amid heightening scrutiny of the agency.

    FDA
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use

    Praxis shares climbed another 40% on a pair of positive updates on two different drugs. Elsewhere, Bristol Myers’ Breyanzi was cleared for its fifth cancer indication and AstraZeneca expanded a rare disease deal.

  • Neuron
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    An Arch-backed biotech raises $53M to fight neurodegeneration

    SciNeuro Pharmaceuticals represents the latest in a string of Arch investments directed at the nervous system, a notoriously challenging area of drug development.

  • Employees of biotechnology company UniQure work in a laboratory.
    Image attribution tooltip
    Courtesy of UniQure
    Image attribution tooltip

    UniQure slides further on outlook for Huntington’s gene therapy

    Finalized minutes from a late-October meeting with the FDA confirm the agency doesn't see the data collected so far as enough to support an approval filing.

  • An illustration of stock market quotes.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Capricor soars on positive results for Duchenne cell therapy

    Shares quadrupled now that the company appears on track to reverse an earlier FDA rejection of what could be the first treatment for heart-related complications of Duchenne.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    Three biotech startups, led by “molecular glue” specialist Triana Biomedicines, raised more than $240 million combined in a trio of financing rounds announced over the course of two days.

    Updated Dec. 4, 2025
  • Bottles of Bristol Myers Squibb's Cobenfy, a new drug for schizophrenia, are arranged in this photo illustration.
    Image attribution tooltip
    Permission granted by Bristol Myers Squibb
    Image attribution tooltip

    After finding ‘irregularities,’ Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis

    Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

  • A drop of liquid is held via a pipette above a row of vials.
    Image attribution tooltip
    deliormanli via Getty Images
    Image attribution tooltip

    Pharvaris’ pill succeeds in late-stage trial for rare swelling disorder

    Phase 3 data could make the Dutch biotech's drug competitive in the increasingly crowded market of hereditary angioedema treatments.

  • A modern architectural design building featuring a red-brick façade with large glass windows displays a prominent sign of the Food and Drug Administration.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Richard Pazdur, FDA drug czar, to retire from agency

    Weeks after being named head of CDER, Pazdur has submitted paperwork to step down at the end of the month, exacerbating what’s already been a turbulent year at the FDA.

    FDA
  • FDA sign
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA details plan to scale back animal tests for some antibody drugs

    The draft guidance issued Tuesday comes as regulators and policymakers have looked for ways to aid U.S. drugmakers amid fast progress by their China-based counterparts.

    FDA
  • An elderly gentleman walks past a hospital sign on September 26, 2007 in London, England. In a report to be released September 27, 2007 the Healthcare Commission outlines care by the NHS Trust should provide further dignity in care to the elderly.
    Image attribution tooltip
    Cate Gillon via Getty Images
    Image attribution tooltip

    UK agrees to boost drug prices to dodge US pharma tariffs

    A deal announced Monday will see the U.K. temporarily sidestep levies on Britain-originated drugs by loosening rules that restrain prices for new medicines.

  • A micrograph of amyloidosis in a human kidney showing amyloid stained with Congo red in the glomeruli and wall of blood vessels.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    With $130M, Protego pushes forward a new type of amyloidosis drug

    The startup’s lead prospect stabilizes abnormal proteins in patients with amyloid “light chain” amyloidosis, an approach that could represent a step forward compared to current therapies. 

  • A U.S. flag flying above a building showing a sign with the word Lilly written in red.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Eli Lilly becomes first drugmaker to hit $1 trillion in market value

    The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that of its drugmaking peers.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Janux sinks on ‘overreaction’ to prostate cancer data; RFK Jr. replaces ACIP chair

    Janux’s “masked” T cell engager had a lower response rate than reported last year. Elsewhere, Lilly dropped Zepbound’s price and ACIP named a new chairman days before a key vaccine meeting.

  • A Regeneron sign in front of a building.
    Image attribution tooltip
    Courtesy of Regeneron Pharmaceuticals
    Image attribution tooltip
    Gene editing

    Regeneron inks gene editing deal with startup Tessera

    The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a potential one-and-done treatment for alpha-1 antitrypsin deficiency.